| GILD |
Report |
Biktarvy Q2 sales |
IN-LINE |
pred ~$3.72B vs. cons $3.697B |
MEDIUM |
| GILD |
Report |
Yeztugo Q2 sales |
BEAT |
pred ~$235M vs. cons $226.8M |
MEDIUM |
| GILD |
Report |
Total revenue Q2 |
IN-LINE |
pred ~$7.45B vs. cons $7.412B |
MEDIUM |
| GILD |
Guide |
FY26 product sales |
UNCHANGED |
guide ~$30.0B-$30.4B vs. cons UNVERIFIED |
LOW |
| GILD |
Guide |
Yeztugo trajectory (FY26) |
BETTER |
guide ~favorable persistence/uptake vs. FY sales consensus $1.050B |
LOW |
| GILD |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.0% |
— |
MEDIUM |
| GILD |
Return |
5-day cumulative residual |
-3.0% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — maintained FY guide leaves revisions constrained |
MEDIUM |